Phase 2 Clinical Results: Chikungunya Vaccine Based on Measles Vector (MV-CHIK) Induces Humoral and Cellular Responses in the Presence of Pre-Existing Anti Measles Immunity
International Journal of Infectious Diseases - Netherlands
doi 10.1016/j.ijid.2018.11.291
Full Text
Open PDFAbstract
Available in full text
Date
February 1, 2019
Authors
Publisher
Elsevier BV